Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries

Research output: Contribution to journalJournal articlepeer-review

DOI

  1. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

    Research output: Contribution to journalJournal articlepeer-review

  1. Three decades of heart transplantation: experience and long-term outcome

    Research output: Contribution to journalJournal articlepeer-review

  2. Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

    Research output: Contribution to journalJournal articlepeer-review

  3. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome

    Research output: Contribution to journalJournal articlepeer-review

  4. Alcohol Intake in Patients With Cardiomyopathy and Heart Failure: Consensus and Controversy

    Research output: Contribution to journalReviewpeer-review

  • Rosa Lauppe
  • Johan Liseth Hansen
  • Anna Fornwall
  • Katarina Johansson
  • Mark H Rozenbaum
  • Anne Mette Strand
  • Merja Väkeväinen
  • Johanna Kuusisto
  • Einar Gude
  • J Gustav Smith
  • Finn Gustafsson
View graph of relations

AIMS: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan. This study aimed to describe the prevalence, clinical characteristics, and mortality of patients with ATTR-CM, using multiple national health registers in Denmark, Finland, Norway, and Sweden.

METHODS AND RESULTS: Transthyretin amyloid cardiomyopathy patients were identified during 2008-2018 using a combination of diagnosis codes for amyloidosis and heart disease and were matched to patients with non-ATTR heart failure (HF). An identical study design was used in each country to facilitate comparison and aggregation of results. A total of 1930 ATTR-CM patients were identified from national health registers in the four countries. In 2018, prevalence of ATTR-CM per 100 000 inhabitants ranged from 1.4 in Denmark to 5.0 in Sweden; a steep increase over time was observed in Sweden and Norway. Median survival from diagnosis was 30 months for ATTR-CM patients and 67 months for matched HF patients. Survival was significantly lower for female than for male ATTR-CM patients (median survival: 22 and 36 months), while no significant difference was observed in the HF cohort.

CONCLUSIONS: This study provides the first nationwide estimates of the prevalence, clinical characteristics, and mortality of patients with ATTR-CM, using identical study design across several countries. Findings corroborate previous case series showing high mortality in ATTR-CM, two-fold higher than for other HF patients and higher in women than men, highlighting the need for more precise and early diagnosis to reduce the disease burden.

Original languageEnglish
JournalESC Heart Failure
Volume9
Issue number4
Pages (from-to)2528-2537
Number of pages10
ISSN2055-5822
DOIs
Publication statusPublished - Aug 2022

Bibliographical note

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

    Research areas

  • Amyloid Neuropathies, Familial/complications, Cardiomyopathies/diagnosis, Female, Heart Failure/complications, Humans, Male, Prealbumin, Prevalence, Quality of Life

ID: 78012600